February 2017—Trovagene has entered into a long-term supply and distribution agreement with Boreal Genomics in which they will merge their respective technologies to co-develop urine and blood ctDNA assay kits. The companies intend to address an unmet need in the liquid biopsy testing market by providing a simple, routine, and low-cost urine and blood ctDNA assay for next-generation sequencing platforms run by laboratories of research institutions, cancer centers, and service facilities around the world.
Read More »Home >> Tag Archives: Trovagene
HPV, other tests, 3/13:74
Trovagene expects to achieve analytical and clinical validation of its urine-based HPV carrier screening test this month in its CLIA laboratory. When validation is complete, the test will be available to clinicians and their patients.
Read More »